New progression in the therapy of blastic plasmacytoid dendritic cell neoplasms

Jingshi Yang, L. Zou
{"title":"New progression in the therapy of blastic plasmacytoid dendritic cell neoplasms","authors":"Jingshi Yang, L. Zou","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.001","DOIUrl":null,"url":null,"abstract":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of rare and highly invasive hematological malignancy. Because of its low incidence, there is still no consensus on its standard treatment. For young patients, high intensity chemotherapy combined with hematopoietic stem cell transplantation is often used. Elderly patients who cannot accept hematopoietic stem cell transplantation receive low intensity chemotherapy. In December 2018, tagraxofusp, a new targeted drug, was approved by the U. S. Food and Drug Administration specially for treatment-naive and previously-treated BPDCN patients (age≥2 years old). Some targeted drugs, such as venetoclax and daratumumab, have certain effects on the treatment of BPDCN. The efficacies of PD-1/PDL-1 inhibitors and anti CD123 chimeric antigen receptor T cell immunotherapy need further researches. \n \nKey words: \nHematological neoplasms; Therapy; Blastic plasmacytoid dendritic cell neoplasms","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"23 1","pages":"577-580"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of rare and highly invasive hematological malignancy. Because of its low incidence, there is still no consensus on its standard treatment. For young patients, high intensity chemotherapy combined with hematopoietic stem cell transplantation is often used. Elderly patients who cannot accept hematopoietic stem cell transplantation receive low intensity chemotherapy. In December 2018, tagraxofusp, a new targeted drug, was approved by the U. S. Food and Drug Administration specially for treatment-naive and previously-treated BPDCN patients (age≥2 years old). Some targeted drugs, such as venetoclax and daratumumab, have certain effects on the treatment of BPDCN. The efficacies of PD-1/PDL-1 inhibitors and anti CD123 chimeric antigen receptor T cell immunotherapy need further researches. Key words: Hematological neoplasms; Therapy; Blastic plasmacytoid dendritic cell neoplasms
母细胞浆细胞样树突状细胞肿瘤治疗的新进展
母浆细胞样树突状细胞肿瘤是一种罕见的高侵袭性血液系统恶性肿瘤。由于其发病率低,对其标准治疗仍未达成共识。对于年轻患者,通常采用高强度化疗联合造血干细胞移植。不能接受造血干细胞移植的老年患者接受低强度化疗。2018年12月,新靶向药物tagraxofusp获美国食品药品监督管理局(fda)批准,专门用于首次治疗和既往治疗过的BPDCN患者(年龄≥2岁)。一些靶向药物,如venetoclax和daratumumab,对BPDCN的治疗有一定的效果。PD-1/PDL-1抑制剂和抗CD123嵌合抗原受体T细胞免疫治疗的疗效有待进一步研究。关键词:血液肿瘤;治疗;母浆细胞样树突状细胞肿瘤
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
12123
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信